Immix Biopharma Q1 net loss widens to USD 10.09 million

Immix Biopharma, Inc.

Immix Biopharma, Inc.

IMMX

0.00
  • Immix Biopharma posted a net loss of USD 10.09 million for the quarter ended March 31, 2026, widening from USD 4.54 million a year earlier.
  • Research and development expense climbed to USD 5.98 million from USD 1.98 million, while general and administrative costs rose to USD 4.82 million from USD 2.71 million.
  • Interest income increased to USD 717,168 from USD 150,219, reflecting interest on money market funds and US Treasuries.
  • Cash, cash equivalents, and short-term investments totaled about USD 90.6 million at March 31, 2026; total assets were about USD 95.8 million with working capital of about USD 81.7 million.
  • NXC-201 received FDA Breakthrough Therapy designation in January 2026 for relapsed/refractory AL amyloidosis, following interim Phase 2 data showing 75% complete responses (15 of 20) and no neurotoxicity observed.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immix Biopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-021764), on May 07, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.